MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (finance)
- RELIGARE ENT.
RELIGARE ENT. Share Price (RELIG)
Here is the latest stock price and chart of Religare Enterprises. For more details, see the Religare Enterprises company fact sheet and quarterly results. For a sector overview, read our finance sector report.
Just Released: The No. 1 Stock to Buy in 2020
| Live BSE Quotes | Jan 28, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)42.35 | Open (Rs) 44.15 | High (Rs) 44.55 | Low (Rs) 42.25 |
| % Change-3.31 | Volume 39,861 | Value (Rs) 1,728,321 | 52-Week H/L 60.60 / 17.05 |
| Live NSE Quotes | Jan 28, 2020 (Close) | ||
|---|---|---|---|
| Price (Rs)42.50 | Open (Rs) 44.30 | High (Rs) 44.65 | Low (Rs) 42.30 |
| % Change-2.41 | Volume 305,574 | Value (Rs) 13,287,066 | 52-Week H/L 59.35 / 16.90 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* -7.64 | P/E Ratio (x) NM | Market Cap (Rs m) 7,552.28 | P/BV (x) 0.45 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
RELIGARE ENT. Share Price Today:
RELIGARE ENT. last traded price was down 3.3% to Rs 42.4 on the BSE. On the NSE, RELIGARE ENT. last traded price was down 2.4% to Rs 42.5. The total volume of shares traded was 0.3 m.
Overall, the benchmark S&P BSE SENSEX was at 40,966.9 (down 0.5%).
Over the last 30 days, the RELIGARE ENT. share price is up 1.2%. And over the last one year, RELIGARE ENT. share price is up 77.2%.
Today's Market
Sensex Ends 188 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)
India share markets witnessed selling pressure during closing hours and ended their day on a negative note. At the closing bell, the BSE Sensex stood lower by 188 points (down 0.5%).
Related Views On News
RELIGARE ENT. Announces Quarterly Results (3QFY19); Net Profit Up 75.2% (Quarterly Result Update)
Feb 22, 2019 | Updated on Feb 22, 2019For the quarter ended December 2018, RELIGARE ENT. has posted a net profit of Rs 103 m (up 75.2% YoY). Sales on the other hand came in at Rs 8 m (down 90.1% YoY). Read on for a complete analysis of RELIGARE ENT.'s quarterly results.
RELIGARE ENT. 2017-18 Annual Report Analysis (Annual Result Update)
Dec 21, 2018 | Updated on Dec 21, 2018Here's an analysis of the annual report of RELIGARE ENT. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of RELIGARE ENT.. Also includes updates on the valuation of RELIGARE ENT..
RELIGARE ENT. Announces Quarterly Results (2QFY19); Net Profit Up 57.9% (Quarterly Result Update)
Nov 29, 2018 | Updated on Nov 29, 2018For the quarter ended September 2018, RELIGARE ENT. has posted a net profit of Rs 128 m (up 57.9% YoY). Sales on the other hand came in at Rs 13 m (down 50.7% YoY). Read on for a complete analysis of RELIGARE ENT.'s quarterly results.
CreditAccess Grameen IPO: Should You Apply to this Interesting Microfinance Play? (IPO)
Aug 7, 2018Should you apply to the IPO of CreditAccess Grameen Ltd?
HDFC AMC IPO: Do Valuations Leave Enough on Table for Investors? (IPO)
Jul 20, 2018Should you subscribe to the IPO of HDFC AMC Ltd?
More Views on NewsMost Popular
How to Buy the Best Safe Stocks in 2020 (The 5 Minute Wrapup)
Jan 17, 2020Don't fall for the safe stocks narrative going around in the stock market these days.
Guess Which Stocks Are Rising at Double the Speed of Sensex (Profit Hunter)
Jan 15, 2020These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.
For 1,000%+ Gains, Follow the 8-Year Cycle in the Stock Market (Fast Profits Daily)
Jan 17, 2020This is how the biggest trading profits are made.
What the Infosys Results Tell Us About the Next Infosys (The 5 Minute Wrapup)
Jan 15, 2020If you're interested in the next Infosys, I'll tell you where to look.
The Best Asset Class to Invest in 2020 (Fast Profits Daily)
Jan 24, 2020Why I'm most bullish on this asset class above all else in 2020.
MoreOUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- A Simple Test to Find out If a Stock Has 100x Potential
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
TRACK RELIGARE ENT.
- Track your investment in RELIGARE ENT. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON RELIGARE ENT.
RELIGARE ENT. - INGERSOLL RAND COMPARISON
COMPARE RELIGARE ENT. WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.